It is with pleasure that we introduce a new section of Diagnostics, named “Clinical Diagnosis and Prognosis”.
The target articles for this section are manuscripts with a focus on clinical diagnosis, stratification, therapy selection (companion diagnostics), and prognostication. Articles focused on developing and evaluating technologies in depth should continue to be submitted to more relevant sections, e.g., “Medical Imaging and Theranostics”, “Pathology and Molecular Diagnostics”, etc. This new section will focus on papers with a clinical focus on established methods.
We hope that with the addition of the section entitled “Clinical Diagnosis and Prognosis”, we can attract more manuscripts within the scope of Diagnostics and also make it more clear to authors where their manuscripts belong. However, the editors and editorial office of Diagnostics will naturally be assisting in allocating manuscripts to the section that best suits their subject matter.
I would also like to take this opportunity to thank all contributors for supporting our journal, which is not only currently thriving, but which we also expect to have an ever-increasing impact on the scientific community. Finally, I would like to thank the editors and editorial office for their excellent work in strengthening our journal’s handling of manuscripts, as well as their tireless work to increase our journal’s visibility and impact.
Conflicts of Interest
The author is the Editor-in-Chief of Diagnostics, no other conflicts of interest exist.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).